In a 2008 review of atypical and anaplastic-meningiomas by Yang et al, the mean overall survival for atypical meningiomas was found to be 11.9 years vs. 3.3 years for anaplastic meningiomas. Mean relapse-free survival for atypical meningiomas was 11.5 years vs. 2.7 years for anaplastic meningiomas. Meningiomas are often vascularized tumors and and it is reasonable to consider antiangiogenic therapy for meningioma. In particular, malignant meningiomas produce high levels of vascular endothelial growth factor (VEGF) and the Avastin blocks this growth factor. It would make sense that Avastin should be effective. However, agressive and anaplastic  meningiomas are rare and there is little known about what works and what does not work for it. Chamberlain found that temozolamide appears ineffective for refractory meningioma. Hydroxyurea is more promising.

Angiogenesis inhibitors, progestins, agents that target fundamental cell signaling pathways, somatostatin analogues, and a variety of other molecular treatments are being investigated.

Norden AD, Drappatz J, Wen PY. Advances in meningioma therapy.Curr Neurol Neurosci Rep. 2009 May;9(3):231-40.

Yang SY et al.: Atypical and anaplastic meningiomas: prognostic implications of clinicopathological features. J Neurol Neurosurg Psychiatry. 2008 May;79(5):574-80.

S. Goutagny et al, Radiographic regression of cranial meningioma in a NF2 patient treated by bevacizumab Ann Oncol (2011) 22(4): 990-991

Chamberlain MC, Tsao-Wei DD, Groshen S. Temozolomide for treatment-resistant recurrent meningioma.Neurology. 2004 Apr 13;62(7):1210-2.

Newton HB. Hydroxyurea chemotherapy in the treatment of meningiomas. Neurosurg Focus. 2007;23(4):E11.

For Lay summary see here

Inoperable medulloblastomas are often treated iwth chemotherapy but there is no randomized prospective evidence to support this. This is especially so in adults, in whom this disease is much less common and in whom it appears to behave distinctly differently. 30% of cases occur in adults. In this case, it is autolgous transplantation that appears to be suggested and after resection.

Autologous transplantation of relapsed disease has support from case reports, series and small prospective trials. There are but a few case reports of allogeneic transplantation for medulloblastoma, some of them from the older literature. Autologous transplantation of relapsed disease has support from case reports, series and small prospective trials. There are but a few case reports of allogeneic transplantation for medulloblastoma, some of them from the older literature. Either kind of stem cell transplantation is not recommended by guidelines after initial treatment. NCCN, on the other hand, lists it as an option for relapsed disease. Unfortunately, at that point, stem cells can no longer be collected because of cranispinal radiation having been performed. It is, therefore, reasonable to collect stem cells before craniospinal radiation is administered, for it precludes stem cell collection in the future. When the cancer recurs, an autologous stem cell transplant is then recommended by NCCCN (AMED-3). For this reason, NCCN recommends collecting stem cellls after the initial remission.

nccn.org, Central Nervous System Cancers, 2013

David D Eisenstat Clinical management of medulloblastoma in adults
Expert Review of Anticancer Therapy October 2004, Vol. 4, No. 5, Pages 795-802

S Secondino Antitumor effect of allogeneic hematopoietic SCT in metastatic medulloblastoma
Bone Marrow Transplantation (2008) 42, 131–133;

Lundberg JH, Weissman DE, Beatty PA, Ash RC. Treatment of recurrent metastatic medulloblastoma with intensive chemotherapy and allogeneic bone marrow transplantation. J Neurooncol 1992; 13: 151–155.

Matsuda Y, Hara J, Osugi Y, Fujisaki H, Takai K, Ohta H et al. Allogeneic peripheral stem cell transplantation using positively selected CD34+ cells from HLA-mismatched donors. Bone Marrow Transplant 1998; 21: 355–360. J Korean Med Sci. 2010 Aug;25(8):1160-1166.

Jun Eun Park et al, Efficacy of High-dose Chemotherapy and Autologous Stem Cell Transplantation in Patients with Relapsed Medulloblastoma: A Report on The Korean Society for Pediatric Neuro-Oncology (KSPNO)-S-053 Study
Korean Med Sci. 2010 Aug;25(8):1160-1166.

Read the Layperson version here.